Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 6Rectal Neoplasms 2Colonic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm Metastasis 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 8Capecitabine 8Fluorouracil 5pembrolizumab 4Oxaliplatin 4Sorafenib 3Leucovorin 3Erlotinib Hydrochloride 3trametinib 2regorafenib 2durvalumab 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Magnetic Resonance Spectroscopy 2Lapatinib 2trifluridine tipiracil drug combination 1tremelimumab 1spartalizumab 1seribantumab 1olutasidenib 1olaparib 1devimistat 1derazantinib 1dehydroftorafur 1cediranib 1cabozantinib 1Trifluridine 1Trastuzumab 1Therapeutics 1Sutures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bile Duct Neoplasms × Trifluridine × Clear all
NCT04072445 2023-08-09

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Mayo Clinic

Phase 2 Completed
28 enrolled 20 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡